Omacor® (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia

Advances in Therapy

Volumn 26, Issue 7, 2009, Pages 675-690

  Rupp, Heinz ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Heart failure; Hypertriglyceridemia; Implantable cardioverter defibrillator; Myocardial infarction; Omacor ; Omega 3 fatty acids; Sudden death

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOCOSAHEXAENOIC ACID; HYPOCHOLESTEROLEMIC AGENT; ICOSAPENTAENOIC ACID; NON PRESCRIPTION DRUG; OLIVE OIL; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SIMVASTATIN; SPIRONOLACTONE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTIARRHYTHMIC AGENT; ANTIDIABETIC AGENT;

CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; DIET SUPPLEMENTATION; DISEASE COURSE; DRUG CAPSULE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FISH; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE REMODELING; HUMAN; HYPERTRIGLYCERIDEMIA; INCIDENCE; INTESTINE ABSORPTION; LIPID COMPOSITION; LOW DRUG DOSE; MORTALITY; NONHUMAN; PATIENT COMPLIANCE; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SUDDEN DEATH; UNSPECIFIED SIDE EFFECT; CARDIOVASCULAR DISEASE; DRUG COMBINATION;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DOCOSAHEXAENOIC ACIDS; DRUG COMBINATIONS; EICOSAPENTAENOIC ACID; HEART FAILURE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIC AGENTS; MEDICATION ADHERENCE; MYOCARDIAL INFARCTION;

EID: 73349122930     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0045-2     Document Type: Review

References (67)

1. Verboom C-N, Oelze R, Rupp H. Saving lives postmyocardial infarction: enhancing the treatment repertoire for prevention of sudden death with highly purified omega-3 fatty acid ethyl esters. London: The Royal Society of Medicine Press Ltd; 2007.
2. H. Rupp D. Wagner T. Rupp L.M. Schulte B. Maisch 2004 Risk stratification by the "EPA+DHA level" and the "EPA/AA ratio" focus on anti-inflammatory and antiarrhythmogenic effects of long-chain omega-3 fatty acids Herz 29 673 685 15580322 10.1007/s00059-004-2602-4 (Pubitemid 40064639)
3. L.D. Lawson B.G. Hughes 1988 Human absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl esters Biochem Biophys Res Commun 152 328 335 3358766 10.1016/S0006-291X(88)80718-6 1:CAS:528:DyaL1cXkt1aju7s%3D
4. S. el Boustani C. Colette L. Monnier B. Descomps A. Crastes de Paulet F. Mendy 1987 Enteral absorption in man of eicosapentaenoic acid in different chemical forms Lipids 22 711 714 2828810 10.1007/BF02533970 1:CAS:528: DyaL1cXjs1KgsA%3D%3D
5. C. Luley H. Wieland J. Grünwald 1990 Bioavailability of omega-3 fatty acids: ethylester preparations are as suitable as triglyceride preparations Akt Ernähr Med 15 123 125
6. I. Ikeda Y. Imasato H. Nagao 1993 Lymphatic transport of eicosapentaenoic and docosahexaenoic acids as triglyceride, ethyl ester and free acid, and their effect on cholesterol transport in rats Life Sci 52 1371 1379 8464336 10.1016/0024-3205(93)90172-Y 1:CAS:528:DyaK3sXitV2qs7Y%3D (Pubitemid 223040463)
7. P.M. Kris-Etherton W.S. Harris L.J. Appel 2002 Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease Circulation 106 2747 2757 12438303 10.1161/01.CIR.0000038493.65177.94 (Pubitemid 35364932)
8. H. Rupp T.P. Rupp D. Wagner P. Alter B. Maisch 2006 Microdetermination of fatty acids by gas chromatography and cardiovascular risk stratification by the "EPA+DHA level" Herz 31 suppl.3 30 49 17575804
9. Die Nationale Verzehrsstudie: Materialien zur Gesundheitsforschung (Band 18) [The National Consumption Study: Materials for Health Research]. Bremerhaven: Wirtschaftsverlag NW; 1991.
10. GISSI-Prevenzione Investigators. 1999 Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico Lancet 354 447 455 10.1016/S0140-6736(99) 07072-5 (Pubitemid 29368922)
11. R. Marchioli F. Avanzini F. Barzi 2001 Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart Eur Heart J 22 2085 2103 11686666 10.1053/euhj.2000.2544 1:STN:280:DC%2BD3MnjvFSgtQ%3D%3D (Pubitemid 33091451)
12. R. Marchioli F. Barzi E. Bomba 2002 Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione Circulation 105 1897 1903 11997274 10.1161/01.CIR.0000014682.14181.F2 1:CAS:528:DC%2BD38XktFajtbc%3D (Pubitemid 34437615)
13. Post myocardial infarction. Secondary prevention in primary and secondary care for patients following a myocardial infarction. NICE web site. May 2007. Available at: http://www.nice.org.uk/nicemedia/pdf/CG48FullGuideline.pdf. Last accessed June 2009.
14. N. Collins A.P. Tighe S.A. Brunton P.M. Kris-Etherton 2008 Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective J Am Coll Nutr 27 659 666 19155425 1:CAS:528:DC%2BD1MXislOis7s%3D
15. R. Turner C.H. McLean K.M. Silvers 2006 Are the health benefits of fish oils limited by products of oxidation? Nutr Res Rev 19 53 62 19079875 10.1079/NRR2006117 1:CAS:528:DC%2BD28XoslWls7g%3D (Pubitemid 44174293)
16. GISSI-HF Investigators. 2008 Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial Lancet 372 1223 1230 10.1016/S0140- 6736(08)61239-8 1:CAS:528:DC%2BD1cXhtF2ku7jF
17. F. Van de Werf J. Bax A. Betriu 2008 Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology Eur Heart J 29 2909 2945 19004841 10.1093/eurheartj/ehn416 1:CAS:528:DC%2BD1MXmtl2hsw%3D%3D
18. P.A. Poole-Wilson K. Swedberg J.G. Cleland 2003 Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial Lancet 362 7 13 12853193 10.1016/S0140-6736(03)13800-7 1:CAS:528: DC%2BD3sXltF2isrs%3D (Pubitemid 36835815)
19. G.E. Billman H. Hallaq A. Leaf 1994 Prevention of ischemia-induced ventricular fibrillation by omega 3 fatty acids Proc Natl Acad Sci U S A 91 4427 4430 8183925 10.1073/pnas.91.10.4427 1:CAS:528:DyaK2cXktVOqu74%3D
20. R. Eickhorn H. Isensee R. Jacob H. Antoni 1992 No obvious influence of dietary fatty acid intake on cardiac sodium current of the rat Pflugers Arch 420 suppl.1 334
21. A. Leaf C.M. Albert M. Josephson 2005 Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake Circulation 112 2762 2768 16267249 10.1161/CIRCULATIONAHA.105.549527 1:CAS:528:DC%2BD2MXhtFCru7bK (Pubitemid 41641669)
22. M. Bryhn H. Hansteen T. Schanche S.E. Aakre 2006 The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters Prostaglandins Leukot Essent Fatty Acids 75 19 24 16806871 10.1016/j.plefa.2006. 04.003 1:CAS:528:DC%2BD28XntlCrurw%3D (Pubitemid 44096989)
23. A. Leaf Y.F. Xiao J.X. Kang G.E. Billman 2005 Membrane effects of the n-3 fish oil fatty acids, which prevent fatal ventricular arrhythmias J Membr Biol 206 129 139 16456723 10.1007/s00232-005-0789-9 1:CAS:528:DC%2BD28XhtFWmt7k%3D (Pubitemid 43199146)
24. P.L. McLennan 2001 Myocardial membrane fatty acids and the antiarrhythmic actions of dietary fish oil in animal models Lipids 36 suppl.1 S111 S114 11837983 10.1007/s11745-001-0692-x 1:CAS:528:DC%2BD38XovVSmtg%3D%3D
25. S.F. Melanson E.L. Lewandrowski J.G. Flood K.B. Lewandrowski 2005 Measurement of organochlorines in commercial over-the-counter fish oil preparations: implications for dietary and therapeutic recommendations for omega-3 fatty acids and a review of the literature Arch Pathol Lab Med 129 74 77 15628911 1:CAS:528:DC%2BD2MXhtVSksbk%3D
26. Dioxins and dioxin-like PCBs in fish oil supplements. Food Standards Agency web site. June 2002. Available at: http://www.food.gov.uk/multimedia/ pdfs/26diox.pdf. Last accessed June 2009.
27. E. Guallar M.I. Sanz-Gallardo P. van't Veer 2002 Mercury, fish oils, and the risk of myocardial infarction N Engl J Med 347 1747 1754 12456850 10.1056/NEJMoa020157 1:CAS:528:DC%2BD38XpsV2jsLs%3D (Pubitemid 35375613)
28. M.H. Davidson E.A. Stein H.E. Bays 2007 Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study Clin Ther 29 1354 1367 17825687 10.1016/j.clinthera. 2007.07.018 1:CAS:528:DC%2BD2sXhtVemurjN (Pubitemid 47348116)
29. M. Lamotte L. Annemans P. Kawalec Y. Zoellner 2006 A multi-country health-economic evaluation of highly concentrated n-3 polyunsaturated fatty acids in the secondary prevention after myocardial infarction Pharmacoeconomics 24 783 795 16898848 10.2165/00019053-200624080-00005 (Pubitemid 44232106)
30. S. Quilici M. Martin A. McGuire Y. Zoellner 2006 A cost-effectiveness analysis of n-3 PUFA (Omacor) treatment in post-MI patients Int J Clin Pract 60 922 932 16893435 10.1111/j.1742-1241.2006.01009.x 1:CAS:528:DC%2BD28XpvVemsb4%3D (Pubitemid 44082283)
31. C.M. Albert H. Campos M.J. Stampfer 2002 Blood levels of long-chain n-3 fatty acids and the risk of sudden death N Engl J Med 346 1113 1118 11948270 10.1056/NEJMoa012918 1:CAS:528:DC%2BD38Xislamtr8%3D (Pubitemid 34984601)
32. D.S. Siscovick T.E. Raghunathan I. King 1995 Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest JAMA 274 1363 1367 7563561 10.1001/jama.274.17.1363 1:CAS:528:DyaK2MXpsl2ksL0%3D
33. W.S. Harris C. von Schacky 2004 The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med 39 212 220 15208005 10.1016/j.ypmed.2004.02.030 1:CAS:528:DC%2BD2cXltVCisL4%3D (Pubitemid 38797975)
34. W.S. Harris B. Assaad W.C. Poston 2006 Tissue omega-6/omega-3 fatty acid ratio and risk for coronary artery disease Am J Cardiol 98 19i 26i 16919513 10.1016/j.amjcard.2005.12.023 1:CAS:528:DC%2BD28XpslWitbg%3D (Pubitemid 44223361)
35. D. Di Stasi R. Bernasconi R. Marchioli 2004 Early modifications of fatty acid composition in plasma phospholipids, platelets and mononucleates of healthy volunteers after low doses of n-3 polyunsaturated fatty acids Eur J Clin Pharmacol 60 183 190 15069592 10.1007/s00228-004-0758-8 1:CAS:528: DC%2BD2cXjvFKnt7c%3D (Pubitemid 38757129)
36. H. Rupp T.P. Rupp P. Alter B. Maisch 2009 N-3 polyunsaturated fatty acids and statins in heart failure Lancet 373 378 379 19186263 10.1016/S0140-6736(09) 60127-6
37. M.T. Kearney K.A. Fox A.J. Lee 2004 Predicting sudden death in patients with mild to moderate chronic heart failure Heart 90 1137 1143 15367507 10.1136/hrt.2003.021733 1:STN:280:DC%2BD2cvlvV2qsg%3D%3D (Pubitemid 39279897)
38. G.C. Fonarow 2008 Statins and n-3 fatty acid supplementation in heart failure Lancet 372 1195 1196 18757087 10.1016/S0140-6736(08)61241-6
39. H.V. Huikuri J.M. Tapanainen K. Lindgren 2003 Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era J Am Coll Cardiol 42 652 658 12932596 10.1016/S0735-1097(03)00783-6 (Pubitemid 37000180)
40. B. Rauch R. Schiele S. Schneider 2006 Highly purified omega-3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction-aims and methods of the OMEGA-study Cardiovasc Drugs Ther 20 365 375 17124558 10.1007/s10557-006-0495-6 1:CAS:528:DC%2BD28XhtlShsLvJ (Pubitemid 44951335)
41. Senges J. Randomized trial of omega-3 fatty acids on top of modern therapy after acute myocardial infarction: the OMEGA-trial. Presented at American College of Cardiology annual meeting; March 30, 2009; Orlando, FL, USA. Available at: http://www.cardiosource.com/rapidnewssummaries/acc09.asp. Last accessed June 2009.
42. R. Marchioli G. Levantesi A. Macchia 2005 Antiarrhythmic mechanisms of n-3 PUFA and the results of the GISSI-Prevenzione trial J Membr Biol 206 117 128 16456722 10.1007/s00232-005-0788-x 1:CAS:528:DC%2BD28XhtFWmt7s%3D (Pubitemid 43199145)
43. Heart Rhythm Society. Late-breaking clinical trial results announced at Heart Rhythm 2009: MADITII trial [press release]. Boston, MA; May 14, 2009. Available at: http://www.hrsonline.org/News/Media/press-releases/MADIT-II- trial09.cfm. Last accessed June 2009.
44. S.H. Hohnloser K.H. Kuck P. Dorian 2004 Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction N Engl J Med 351 2481 2488 15590950 10.1056/NEJMoa041489 1:CAS:528:DC%2BD2cXhtVGksbnN (Pubitemid 39603155)
45. A.M. Gillis 2004 Prophylactic implantable cardioverter-defibrillators after myocardial infarction-not for everyone N Engl J Med 351 2540 2542 15590957 10.1056/NEJMe048230 1:CAS:528:DC%2BD2cXhtVGksbbJ (Pubitemid 39603159)
46. ACC.09/i2 Summit clinical trial summary slides. American College of Cardiology web site. Available at: http://www.cardiosource.com/img/ACC09- Compilation.ppt. Last accessed June 2009.
47. Alter P, Rupp H, Rominger MB, et al. A new method to assess ventricular wall stress in patients with heart failure and its relation to heart rate variability. Int J Cardiol. 2008; Oct 24 [Epub ahead of print].
48. P. Alter H. Rupp M.B. Rominger 2009 Depression of heart rate variability in patients with increased ventricular wall stress Pacing Clin Electrophysiol 32 suppl.1 S26 S31 19250107 10.1111/j.1540-8159.2008.02223.x
49. P. Alter H. Rupp M.B. Rominger K.J. Klose B. Maisch 2008 A new methodological approach to assess cardiac work by pressure-volume and stress-length relations in patients with aortic valve stenosis and dilated cardiomyopathy Pflugers Arch 455 627 636 17721708 10.1007/s00424-007-0323-2 1:CAS:528:DC%2BD2sXhtlCgt7%2FF (Pubitemid 350160477)
50. P. Alter H. Rupp M.B. Rominger 2007 Relation of B-type natriuretic peptide to left ventricular wall stress as assessed by cardiac magnetic resonance imaging in patients with dilated cardiomyopathy Can J Physiol Pharmacol 85 790 799 17901889 10.1139/Y07-076 1:CAS:528:DC%2BD2sXht1ajtbfI (Pubitemid 350144739)
51. P. Alter H. Rupp M.B. Rominger 2008 B-type natriuretic peptide and wall stress in dilated human heart Mol Cell Biochem 314 179 191 18461428 10.1007/s11010-008-9779-4 1:CAS:528:DC%2BD1cXntFKnu7c%3D
52. L. Calo L. Bianconi F. Colivicchi 2005 N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial J Am Coll Cardiol 45 1723 1728 15893193 10.1016/j.jacc.2005.02. 079 1:CAS:528:DC%2BD2MXktVOjt7w%3D (Pubitemid 40704512)
53. A. Macchia S. Monte F. Pellegrini 2008 Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction Eur J Clin Pharmacol 64 627 634 18309477 10.1007/s00228-008-0464-z 1:CAS:528:DC%2BD1cXkvFymurk%3D
54. D.M. Ninio K.J. Murphy P.R. Howe D.A. Saint 2005 Dietary fish oil protects against stretch-induced vulnerability to atrial fibrillation in a rabbit model J Cardiovasc Electrophysiol 16 1189 1194 16302902 10.1111/j.1540-8167.2005.50007.x (Pubitemid 43920007)
55. G.R. Li H.Y. Sun X.H. Zhang 2009 Omega-3 polyunsaturated fatty acids inhibit transient outward and ultra-rapid delayed rectifier K+currents and Na+current in human atrial myocytes Cardiovasc Res 81 286 293 19029136 10.1093/cvr/cvn322 1:CAS:528:DC%2BD1MXntVOjtw%3D%3D
56. H. Bays 2008 Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians Drugs Today (Barc) 44 205 246 10.1358/dot.2008.44.3.1166387 1:CAS:528:DC%2BD1cXmtlSntbY%3D (Pubitemid 351669107)
57. H. Rupp R. Wahl M. Hansen 1992 Influence of diet and carnitine palmitoyltransferase I inhibition on myosin and sarcoplasmic reticulum J Appl Physiol 72 352 360 1537736 1:CAS:528:DyaK38XitFensbk%3D
58. J.G. Robinson N.J. Stone 2006 Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids Am J Cardiol 98 39i 49i 16919516 10.1016/j.amjcard.2005.12.026 1:CAS:528:DC%2BD28XpslWitbc%3D
59. M.H. Davidson 2006 Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids Am J Cardiol 98 27i 33i 16919514 10.1016/j.amjcard. 2005.12.024 1:CAS:528:DC%2BD28XpslWitbk%3D (Pubitemid 44223362)
60. R.K. Berge L. Madsen H. Vaagenes K.J. Tronstad M. Gottlicher A.C. Rustan 1999 In contrast with docosahexaenoic acid, eicosapentaenoic acid and hypolipidaemic derivatives decrease hepatic synthesis and secretion of triacylglycerol by decreased diacylglycerol acyltransferase activity and stimulation of fatty acid oxidation Biochem J 343 191 197 10493929 10.1042/0264-6021:3430191 1:CAS:528:DyaK1MXmvVyju7k%3D (Pubitemid 29473895)
61. R. Scott R. O'Brien G. Fulcher 2009 Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study Diabetes Care 32 493 498 18984774 10.2337/dc08-1543 1:CAS:528:DC%2BD1MXjvVyqt7s%3D
62. J.C. Fruchart 2009 Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease Atherosclerosis 205 1 8 19386311 10.1016/j.atherosclerosis.2009.03.008 1:CAS:528:DC%2BD1MXnsFags70%3D
63. J.V. Donadio Jr. T.S. Larson E.J. Bergstralh J.P. Grande 2001 A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy J Am Soc Nephrol 12 791 799 11274240 1:CAS:528: DC%2BD3MXjtVWgt78%3D
64. M.L. Burr 2007 Secondary prevention of CHD in UK men: the Diet and Reinfarction Trial and its sequel Proc Nutr Soc 66 9 15 17343767 10.1017/S0029665107005241 (Pubitemid 46748239)
65. H. Rupp T.P. Rupp B. Maisch 2005 Fatty acid oxidation inhibition with PPARalpha activation (FOXIB/PPARalpha) for normalizing gene expression in heart failure? Cardiovasc Res 66 423 426 15914105 10.1016/j.cardiores.2005.03.023 1:CAS:528:DC%2BD2MXks1antbg%3D (Pubitemid 40725753)
66. H. Rupp T.P. Rupp P. Alter B. Maisch 2006 Acute heart failure- basic pathomechanism and new drug targets Herz 31 727 735 17149674 10.1007/s00059-006-2911-x (Pubitemid 44934645)
67. C.G. Brilla R.C. Funck H. Rupp 2000 Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease Circulation 102 1388 1393 10993857 1:CAS:528:DC%2BD3cXntFKksbY%3D